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Abstract
Background: Ajulemic acid (AjA) is a synthetic analogue of tetrahydrocannabinol that can prevent and limit progression
of skin fibrosis in experimental systemic sclerosis. In this study we investigated whether AjA also prevents and modulates
lung fibrosis induced by bleomycin (BLM) when administered in mice during the inflammatory or the fibrogenic phase
of the model.
Methods: The anti-inflammatory and antifibrotic efficacy of AjA was evaluated in DBA/2 mice treated orally once a day
starting either at day 0 (preventive treatment) or at day 8 (therapeutic treatment) after a single intratracheal instillation
of BLM. AjA was given at a dose of 1 mg/kg or 5 mg/kg. Mice were sacrificed at day 8, 14 and 21 after BLM and lungs
were processed for histology and morphometry, and examined for HO-proline content and for the expression of
transforming growth factor beta 1 (TGF-β1), phosphorylated Smad2/3 (pSMAD2/3), connective tissue growth factor
(CTGF), alpha-smooth muscle actin (α-SMA) and peroxisome proliferator-activated receptor-gamma (PPAR-γ).
Results: In the 1st week after BLM challenge, an acute inflammation characterized by neutrophil and macrophage
accumulation was the main change present in lung parenchyma. The “switch” between inflammation and fibrosis
occurs between day 8 and 14 after BLM instillation and involves the bronchi and vasculature. In the subsequent
week (at day 21 after BLM instillation) bronchiolocentric fibrosis with significant increase of tissue collagen develops.
The fibrotic response evaluated by morphometry and quantified as HO-proline in lung tissue at day 21 after BLM
treatment was significantly reduced in mice receiving either AjA in the inflammatory or in early fibrogenic phase. AjA
induces marked change in the expression pattern of products implicated in fibrogenesis, such as TGF-β1, pSMAD2/3,
CTGF and α-SMA. In addition, AjA increases significantly the number of PPAR-γ positive cells and its nuclear localization.
Conclusions: AjA treatment, starting either at day 0 or at day 8 after BLM challenge, counteracts the progression of
pulmonary fibrosis. The anti-fibrotic effectiveness of AjA is irrespective of timing of compound administration. Further
clinical studies are necessary to establish whether AjA may represent a new therapeutic option for treating fibrotic lung
diseases.
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Background
Pulmonary fibrosis (PF) is a progressive disorder charac-
terized by the disruption of the normal tissue architec-
ture and function of the lung. Its main feature is the
excessive synthesis and deposition of extracellular matrix
in the distal airspace [1]. PF may be a fatal complication
of chemotherapy and thoracic radiation. Five to 40 % of
cancer patients develop drug-induced pulmonary injury,
inflammation and fibrosis, resulting in significant mor-
bidity. Mortality rates range from 2 to 80 % of cases, de-
pending on the causal agent [2]. The probability to
trigger a form of iatrogenic PF rises with cumulative
doses of drugs or radiation and limits the use of other-
wise effective therapies [3, 4]. Although some forms of
lung fibrosis associated with some conditions (such as,
desquamative interstitial pneumonia, bronchiolitis oblit-
erans organizing pneumonia, BOOP, sarcoidosis etc.)
can be effectively treated with steroids (1), other forms
of PF including Idiopathic Pulmonary Fibrosis (IPF) or
chemo- and radiotherapy-induced PF are usually steroid-
insensitive. In the latter forms of PF and in particular in
IPF, current therapies only relieve symptoms and do not
alter the course of the disease [1, 5, 6]. Possibly because of
the complex nature of lung fibrosis and in particular of
the mechanisms underlying the development of IPF, pa-
tients respond poorly to available anti-fibrotic drugs [7].
Hence, there is an unfulfilled need for effective anti-
fibrotic drugs either to treat IPF or to employ in associ-
ation with cancer therapies in order to increase drug
dosage and lower the risk of lung toxicity.
Different models of PF have been developed over the
years to investigate the potential therapies for IPF, but
unfortunately most of them mimic some, but never all
features of human IPF, especially the progressive and ir-
reversible nature of the condition. The bleomycin (BLM)
model in rodents is the most commonly used.
BLM is a glycopeptide antibiotic [8] with potent anti-
tumor activity against a wide range of tumors [9]. How-
ever, the therapeutic efficacy of BLM is limited by its
side-effects, which include PF [10, 11].
In rodents, intratracheal administration of BLM in-
duces acute alveolitis and interstitial inflammation,
which are characterized by the recruitment of leukocytes
within 1 week [12]. The “switch” between inflammation
and fibrosis occurs between day 8 and 14 after BLM in-
stillation and the fibrotic response is characterised by
fibroblast proliferation and synthesis of extracellular
matrix [13]. Various types of resident cells, including
macrophages, fibroblasts, endothelial and epithelial cells,
or migrating cells such as neutrophils and fibrocytes,
have been implicated in the development of PF [14].
Over the years, numerous agents have been shown to
inhibit fibrosis in BLM model. However, to date none of
these compounds are used in the clinical management
of IPF and none has shown a comparable anti-fibrotic
efficacy in humans. The most part of these compounds
was tested in BLM model “in a preventive manner” dur-
ing the first 7 days after BLM administration when, an
interference with the inflammatory response can modify
or abolish the following fibrogenic phase. Actually, in
human IPF the inflammation phase is not recognized
and patients come to the attention of the physician only
in the advanced fibrogenic phase of the disease.
Only few drugs have been shown to reduce fibrosis
when used during the fibrogenic phase of BLM model
but unfortunately most of them were abandoned after
clinical trials for lack of benefit or for their toxicity [for
a review see 15].
In previous studies we demonstrated that some syn-
thetic cannabinoids are effective in preventing dermal
collagen accumulation in a model of systemic sclerosis
[16, 17]. In particular, ajulemic acid (AjA), a no-toxic
synthetic analogue of tetrahydrocannabinol, exerts po-
tent anti-fibrotic effects in experimental models of sys-
temic sclerosis.
Given the necessity to discover new drugs for the ther-
apy of human pulmonary fibrosis we decided to evaluate
the potential anti-fibrotic effect of AjA either in the early
period of BLM-induced inflammation or in the fibro-




Male DBA/2 mice (Charles River, Calco, Italy) of 6–8
weeks of age were used in this study. Mice were group-
housed in individual cages in climate-controlled animal
quarters and given water and food (Mucedola Global
Diet 2018, Harlan, Italy) ad libitum, while a 12-h on 12-
h off light cycle was maintained. All protocols were ap-
proved by the University of Siena Committee for Animal
Experimentation - OBA (Project G 2207/09 #6; G 2007/
11 #2). The animal experimentation was conducted in
conformity with the “Guiding Principles for Research in-
volving Animals and Human Beings”.
Experimental design
Saline and BLM groups received a single intratracheal
(i.tr.) instillation of 50 μl of saline solution (control sa-
line) or 0.1 μg of BLM (Sanofi-Aventis S.p.A, Milan) in
50 μl of saline solution. We defined the day of BLM ad-
ministration as day 0, allowing the association of this
time point with the schedule of compound administra-
tion. Six groups of 14 animals each were used in this
study to evaluate the efficacy of AjA (Corbus Pharma-
ceuticals, Norwood, MA, USA) by starting the treatment
in the inflammatory (at day 0) or in early fibrogenic
phase (at day 8 after BLM application) (Fig. 1a). This
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methodological approach was chosen in order to evalu-
ate whether AjA treatment is able to interfere with the
inflammatory response and/or with the fibrogenic
changes caused by BLM instillation.
In the “preventive protocol of treatment”, experimental
groups received per os either 1 mg or 5 mg/Kg of AjA in
100 μl safflower oil, at 1 h before BLM treatment and
then once a day for the following 8, 14 and 21 days. In
the “therapeutic protocol of treatment”, additional two
groups of animals received daily per os AjA at a dose of
1 mg and 5 mg/Kg, respectively, starting at day 8 after
BLM instillation for the following 14 and 21 days
(Fig. 1a).
BLM i.tr. instillation was performed under light
ether anaesthesia as reported in details in previous
papers [18, 19].
At the selected time points (Fig. 1a), the animals were
injected with an overdose of pentobarbital sodium. The
lungs were then excised and processed for histological
and biochemical analysis.
To exclude the interference of safflower oil (used as AjA
vehicle) in our study, we carried out preliminary experi-
ments by treating per os animals with safflower oil. Briefly,
in this preliminary experiment, 5 mice/group were treated
per os with 100 μl safflower oil 1 h before instillation with
saline or BLM, and then once a day for the following 14
and 21 days. At day 14 and 21, mice were sacrificed and
lungs were analysed by morphology. No changes were de-
tected in mice treated with safflower oil alone before saline
administration. Additionally, no appreciable morpho-
logical differences were observed between groups receiv-
ing safflower oil plus BLM or BLM alone.
Fig. 1 Scheme of Treatment and Criteria for Histologic Fibrosis Scores. a “Preventive” and “Therapeutic” Animal Treatment with Ajulemic Acid
(AjA) in Bleomycin (BLM) Model. b Histologic Lung Fibrosis Score was determined in individual animals by multiplying Ashcroft Score by the
mean of extent of fibrosis scored from 1 to 5 as reported in figure
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Histology and morphometry
The lungs of seven mice from different groups of treat-
ment were fixed i.tr. with buffered formalin (5 %) at a
constant pressure of 20 cm H2O at least for 24 h. Lungs
were fixed, dehydrated, cleared in toluene, and embed-
ded in paraffin.
Histopathological assessment of lung fibrosis
Lungs of seven animals from each experimental groups
excised 21 days after BLM or saline treatment were used
for the histopathological assessment of fibrosis.
Three systems were used to assess fibrosis on Haema-
toxylin & Eosin and Masson’s trichrome stained lung
sections (5 μm thick) (see Fig. 1b) [20, 21]. The first
scoring system was used to determine the extent of the
fibrotic areas by calculating the percentage of the total
lung surface involved. The second scoring system was
used to evaluate the severity of the lesions. This was
achieved by using the Ashcroft scoring system adapted
by Theiss [20, 21] (see Fig. 1b). Finally, we determined
the mean histological score by taking into account both
the severity (Ashcroft score) and the extent of the fi-
brotic lesions [22], which was scored from 1 to 5 on the
basis of the mean percentage of fibrotic areas involved
in individual animals. This was assessed for each animal,
and multiplied by the mean Ashcroft score (Fig. 1b).
The extent of fibrotic areas was carried out on Mas-
son's trichrome stained slides at final magnification of
x100–200. For stereological determination, randomly
sampled areas of lungs were analyzed using stereology
grid-counting techniques to quantify areas of fibrotic
disease.
Immunohistochemistry
Tissue sections (5 μm thick) from the different groups of
mice were stained for transforming growth factor
(TGF)-ß1, connective tissue growth factor (CTGF),
alpha-smooth muscle actin (α-SMA), phosphorylated
Smad2/3 (pSMAD2/3) and peroxisome proliferator-
activated receptor gamma (PPARγ).
The sections were pre-treated with 3 % hydrogen per-
oxide for blocking the endogenous peroxidase. On
PPARγ sections, no hydrogen peroxide pre-treatment
was performed. Antigen retrieval was performed for the
immunodetection of TGF-ß1, pSMAD2/3 and PPARγ by
heating the sections in a microwave for 20 min in
0.01 M pH 6.0 citrate buffer and allowing to cool slowly
to room temperature (RT). All the sections were incu-
bated with 3 % bovine serum albumin for 30 min at room
temperature to block non-specific antibody binding.
Sections were incubated overnight at 4 °C in the pri-
mary antibody: rabbit Ab to mouse TGF-ß1 (Insight Bio-
technology LTD, Wembley, UK) diluted 1:20; rabbit Ab
to mouse CTGF (Abcam, Cambridge, UK) diluted 1:200;
rabbit Ab to mouse pSMAD2/3 (Millipore, Merck
KGaA, Darmstadt, Germany) diluted 1:100; rabbit Ab to
mouse PPARγ (Cell Signaling Technology, Beverly, MA)
diluted 1:100.
After rinsing with PBS, TGF-ß1 and pSMAD2/3 slides
were incubated with sheep anti-rabbit IgG (1:200) for
30 min at RT followed by incubation with peroxidase-
antiperoxidase complex, prepared from rabbit serum.
CTGF sections were incubated with the appropriate
biotin-conjugated secondary antibody and subsequently
with streptavidin/peroxidase solution.
Colour development was performed using 3,3′-diami-
nobenzidine tetra hydrochloride as a chromogen (DAB;
Vector Laboratories, Burlingame, CA).
The sections for PPARγ were rinsed in PBS and incu-
bated with goat polyclonal anti-rabbit biotinylated IgG
(1:200) (Vector Labs, Burlingame, CA) for 30 min. at
room temperature. The staining was revealed by adding
Streptavidin-alkaline phosphatase (BD Pharmingen, Buc-
cinasco, Italy).
After rinsing in 0.01 M PBS containing 0.1 % Triton
X-100, the alkaline phosphatase reaction was developed
with NBT/BCIP stock solution (Roche Diagnostics,
Milan, Italy) as chromogen diluted in 0.1 M TRIS buffer,
pH 9.5, 0.05 M MgCl2, 0.1 M NaCl, 2 mM levamisole.
α-SMA protein was immunohistochemically evaluated
on paraffin sections using mouse monoclonal α-SMA
Ab (Sigma, St. Louis, MO, USA) diluted 1:200. Reaction
was visualized using the M.O.M. immunodetection kit
(Vector Laboratories, Burlingame, CA) and DAB as sub-
strate. The Vector M.O.M. immunodetection kit is de-
signed specifically to localize mouse primary monoclonal
and polyclonal antibodies on mouse tissues by using a
novel blocking agent and reducing undesired back-
ground staining.
As negative controls, all primary antibodies were re-
placed by non-immunised specific serum.
Immunohistological score for pSMAD2/3, CTGF and
PPAR-γ was carried out at x200 magnification. The
number of positive cells in lung sections (10 random
microscopic fields per lung section in 5 different sec-
tions) was counted manually in a blinded manner and
averaged. Cells that showed nuclear PPAR-γ positivity
were enumerated.
The extent of α-SMA positive areas was carried out on
immunostained slides at x200 final magnification. For
stereological determination randomly sampled areas of
lungs were analyzed using stereology grid-counting tech-
niques to quantify positive areas.
Hydroxyproline assay
To quantify lung collagen at the different time points, 7
animals from different groups were used. Mice were
anaesthetized with sodium pentobarbital and sacrificed
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by severing the abdominal aorta. After thoracotomy, the
thoracic viscera were immediately removed. The lungs
were weighed and homogenized (1:9, weight: volume (w:
v). An aliquot was hydrolysed in 6 N HCl and the
remaining part was used for Western Blot analysis. Hy-
droxyproline (HO-proline) was determined in lung hy-
drolysates according to the method of Kivirikko et al.
[23, 24] and data were expressed as μg · lung−1.
ELISA assay
Quantification of TGF-β1 levels in tissue lung was mea-
sured by ELISA following the manufacturer’s protocol
(R&D Systems, Minneapolis, MN).
Western blotting
Western blotting was used to determine α-SMA expres-
sion in pulmonary tissues from 7 animals of the different
groups. The protein concentration of each sample was
assayed using Bio-Rad Bradford protein assay. Fifty mi-
crograms of lung homogenate were electrophoresed
through a SDS-polyacrylamide gel and transferred to a
nitrocellulose membrane. After blocking with 5 % non-
fat powdered milk in Tris-buffered saline/Tween 20, the
blots were incubated with a mouse monoclonal anti-α-
SMA Ab (1:8000; Sigma, St. Louis, MO, USA) at 4 °C
overnight. After washing with Tris-buffered saline/
Tween 20, they were incubated with a secondary anti-
mouse conjugated to horseradish peroxidase (1:10000)
(Roche Molecular Biochemicals, Milan, Italy). The blot
was developed using the enhanced chemiluminescence
method ECL-Kit Lumi-LightPlus (Roche Molecular
Biochemicals, Milan, Italy) according to the manufac-
turer’s instructions. The membranes were re-probed
with rabbit polyclonal to glyceraldehyde 3phosphate de-
hydrogenase (GAPDH) (1:2500) (Abcam, Cambridge,
UK) to normalize for protein loading. Each band was
scanned by densitometry analysis and normalized to
GAPDH.
Statistical analysis
The significance of the differences was calculated using
one-way analysis of variance. A p value of less than 0.05
was considered significant.
Results
To test the hypothesis that AjA administration prevents
the development of pulmonary fibrosis, we used the
single-dose model of i.tr. BLM instillation in mice [25]
and started AjA treatments at the same day of BLM ad-
ministration (Fig. 1a, Groups 3 and 4) or at day 8 during
the fibrogenic phase (Fig. 1a, Groups 5 and 6).
AjA treatment limits the development of pulmonary
fibrosis when used in “preventive manner”
The exposure to BLM in DBA/2 mice resulted at day 8
after treatment in the development of sub-pleural areas
of inflammation that extended into the lung parenchyma
and involved the bronchi and vasculature (Fig. 2, panel
a). Later on, more severe areas of fibrosis with marked
disruption of the alveolar unit and increased deposition
of collagen were observed in BLM-treated mice.
In particular, 14 days after BLM, DBA/2 mice showed
large areas of inflammation and “provisional” matrix
(Fig. 2, panel b, arrow). At day 21, consolidated areas of
fibrosis with collagen accumulation (“sea green areas”)
were evident (Fig. 2, panel c) and involved 36.84 ±
11.47 % of the lungs (Fig. 2d).
Control lungs of saline-instilled mice showed a normal
architecture (Fig. 2, panels a–c). The morphological
examination of lung sections revealed that AjA adminis-
tered in preventive manner (Groups 3 and 4 of Fig. 1a)
markedly reduced the number of inflammatory cells at
day 8 (Fig. 2, panel a) and attenuated the collagen depos-
ition and destruction of lung architecture at day 14
(Fig. 2, panel b) and 21 (Fig. 2, panel c) as compared to
mice treated with BLM alone (Fig. 2, panels a–c).
Twenty-one days after BLM administration, DBA/2
mice treated with AjA showed a marked and significant
reduction of fibrotic areas (Fig. 2d) as well as of Ashcroft
(Fig. 2e) and histological scores (Fig. 2f ).
The effects of AjA in reducing collagen accumulation
were also determined by analysing lung HO-proline con-
tent of mice after BLM exposure. The i.tr. instillation of
BLM in mice resulted in a significant increase in lung
HO-proline at day 14 after treatment that peaked at day
21. AjA treatment (1 mg/kg/day and 5 mg/kg/day) sig-
nificantly reduced total lung HO-proline content in sam-
ples of BLM-instilled mice at day 21 after treatment
(Fig. 2g).
In control animals, a mild positivity of TGF-β1 was
seen on some alveolar macrophages and some cells of
the airways epithelium (Fig. 3, panels a and b). In BLM-
instilled mice, the intensity of TGF-β1 staining (arrows)
markedly increased on the cells at both day 8 and day 14
after BLM treatment (Fig. 3, panels a and b, respect-
ively). TGF-β1 positivity was also observed on some al-
veolar epithelial cells and the extracellular matrix
(arrowheads) present in fibrotic areas (Fig. 3, panel b). A
less widespread and intense TGF-β1 reaction was seen
in mice treated with AjA (1 mg/kg/day and 5 mg/kg/
day) at day 8 (Fig. 3, panel a) and 14 (Fig. 3, panel b).
Additionally, a significant effect of AjA in reducing
TGF-β1 tissue levels was demonstrated by ELISA
(Fig. 3c).
The increased expression of TGF-β1 observed in
mice after BLM treatment was accompanied by a
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decreased expression of PPAR-γ. In lungs from con-
trol mice, PPAR-γ was detectable in several different
types of cells, where it appeared to be localized in the
cytoplasm (Fig. 4a, inset). After BLM treatment a
progressive loss of PPAR-γ expression was observed
mainly in the fibrotic areas (Fig. 4, panel a). Adminis-
tration of AjA (1 mg/kg/day and 5 mg/kg/day), in
BLM treated mice, markedly increased PPAR-γ
Fig. 2 AjA reduces inflammation and provisional matrix deposition in BLM-lung and prevents the development of lung fibrosis when administered in
preventive manner in BLM treated mice. a Lung slides of mice from the different experimental groups at day 8 from the start of treatment are shown.
Haematoxylin & Eosin staining, scale bars = 60 μm. b Lung slides from mice at day 14 from the start of treatment. Note the large area of inflammation
with presence of “provisional” matrix (arrows) in mice treated with BLM alone. Mild changes are seen in mice treated with AjA at a dose of 1 mg/Kg
and 5 mg/Kg. Masson’s trichrome staining, scale bars = 60 μm. c Lung slides from mice of the different experimental groups at day 21 from the start of
treatment. Consolidated areas of fibrosis are evident in BLM-treated mice. Reduced areas of fibrosis are seen in groups receiving in the same day of
BLM delivery AjA at a dose of 1 mg/Kg and 5 mg/Kg. Masson’s trichrome staining, scale bars = 60 μm. d Extent of the fibrotic areas as percent of
surface area involved. Data are reported as mean ± SD. *p < 0.05 vs control group. † p < 0.05 vs BLM group. e Ashcroft score: data are reported as mean
± SD. *p < 0.05 vs control group. † p < 0.05 vs BLM group. f Histological score: data are reported as mean ± SD. *p < 0.05 vs control group. † p < 0.05 vs
BLM group. g Lung HO-proline expressed as μg/lung in the various experimental groups. Data are reported as mean ± SD. *p < 0.05 vs control group.
† p < 0.05 vs BLM group
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positivity, with a prevalent nuclear localization (Fig. 4,
a inset).
In Fig. 4d, we report the values of the immunohisto-
chemical score of cytoplasmic and nuclear PPAR-γ stain-
ing in the various experimental groups analysed in the
preventive study.
An immunohistochemical faint reaction for pSMAD2/
3 was seen in lungs of control mice (Fig. 4, panel b). It is
worth to note that, the enhanced nuclear expression and
retention of pSMAD2/3 observed in BLM treated mice
was efficiently counteracted by AjA administration. In
Fig. 4e, we report the values of the immunohistochemi-
cal scores of pSMAD2/3 from the various experimental
groups.
A mild reaction for the fibrogenic cytokine CTGF was
appreciated in lung slices from control mice (Fig. 4,
panel c). At day 14 after BLM treatment an increased
amount of CTGF was found in fibrotic areas of lung tis-
sue. CTGF was markedly reduced in tissue samples of
mice treated with AjA both at the dose of 1 mg/kg/day
and 5 mg/kg/day. In Fig. 4f we report the values of the
immunohistochemical score of CTGF in the various ex-
perimental groups.
In lungs of control mice (Fig. 5, panel a and b), α-
SMA was only found around arterial vessels and bron-
chial and bronchiolar walls. BLM treatment induced
increased expression of α-SMA in mouse lungs both at
day 14 and 21. This protein is a sensitive indicator of
Fig. 3 AjA treatment reduces the expression of TGF-β1 in lungs of BLM-treated mice. Representative immunohistochemical staining of TGF-β1 in
the different experimental groups at day 8 a and 14 b are shown. An immunopositive reaction is observed on epithelial cells and alveolar macrophages
as marked by arrows. TGF-β1 positive cells are also seen in consolidated areas of fibrosis (arrowheads). Scale bars = 60 μm. c Tissue levels of TGF-β1
measured by ELISA at day 14 from BLM challenge. Data are reported as mean ± SD. *p < 0.05 vs control group. † p < 0.05 vs BLM group
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myofibroblast differentiation and thus is a very good
indicator of the presence of active fibrogenic cells in
lung tissue. The appearance of newly differentiated α-
SMA positive cells was markedly reduced by AjA
treatment both at day 14 (Fig. 5, panel a) and 21
(Fig. 5, panel b) after BLM instillation. In Figs. 5, c
and d, we report the immunohistochemical scores
and the Western blot analysis of α-SMA in mouse
lungs from the various experimental groups used in
the preventive study.
Delayed treatment with AjA effectively limits pulmonary
fibrosis progression by decreasing fibrogenesis
In order to test the therapeutic value of AjA in prevent-
ing fibrogenesis, animals were treated with the synthetic
cannabinoid in the fibrogenic stage of BLM lung,
Fig. 4 AjA treatment is followed by enhanced PPAR-γ expression, reduced pSMAD2/3 nuclear localization and reduced expression of CTGF.
a Representative immunohistochemical staining of PPAR-γ in lung section from animals of the different experimental groups at 14 days after BLM
delivery. Scale bars = 60 μm. b Immunohistochemical staining of pSMAD2/3 in lung section from control mouse, BLM-treated mouse and mice
receiving in the same day of BLM delivery AjA at a dose of 1 mg/Kg and 5 mg/Kg, at 14 days after BLM delivery. Scale bars = 60 μm. c Representative
immunohistochemical staining of CTGF in lung section from the different experimental groups. Scale bars = 60 μm. d–f Immunohistochemical scores
relative to cytoplasmic and nuclear localization of PPAR-γ, pSMAD2/3 and CTGF positive cells from the various experimental groups analysed in the
preventive study. Data are reported as mean ± SD. *p < 0.05 vs control group. † p < 0.05 vs BLM group
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starting at day 8 from BLM administration (Fig. 1,
Groups 5 and 6). Daily treatment of mice at a dose of 1
and 5 mg/Kg markedly reduced at different extent the fi-
brotic reaction observed at day 21 (Fig. 6a). For com-
parison, representative lung histologic section from
control and BLM treated mice are reported in the same
panel. In Fig. 6b the histologic score of fibrosis of lungs
from the various experimental groups analysed in fibro-
genic study is presented. The decrease in collagen
deposition by delayed AjA treatment observed in histo-
logical slides after Masson-trichrome staining (Fig. 6,
panels a and b) was also confirmed by the decrease of
total lung HO-proline content (Fig. 6c).
Representative immuno-histochemical reactions for
TGF-β1, pSMAD2/3 and CTGF detected at 14 days after
BLM administration are reported in Fig. 7, panels a, b
and c, respectively. The reduction of fibrosis score ob-
served in mice treated with AjA (at a dose of 1 and
5 mg/Kg) was preceded at day 14 by a low expression
(Fig. 7, panel a) and decreased tissue levels of TGF-β1
(Fig. 7d), by a low nuclear expression and reduced nu-
clear retention of pSMAD2/3 (Fig. 7b) and by a marked
reduction of CTGF (Fig. 7c) as compared to mice treated
with BLM alone. A faint reaction for these products was
observed in lung tissues from control mice. The values
of immunohistochemical scores for pSMAD2/3 and
Fig. 5 AjA treatment is followed by a reduced expression of α-SMA. Representative immunohistochemical staining of α-SMA in lung sections from
animals from the different experimental groups at day 14 a and 21 b after BLM treatment, receiving AjA at 1 h before BLM challenge. Scale bars = 60 μm.
c Immunohistochemical score for α-SMA in the different experimental groups. Data are reported as mean ± SD. *p< 0.05 vs control group. † p< 0.05 vs
BLM group. d Representative Western blot analysis of α-SMA from total lung samples of control, BLM-instilled and AjA-treated mice at 14 and 21 days
after the start of treatments. Lanes (1) and (3) = Control samples. Lanes (2) and (4) = BLM-instilled mice at 14 and 21 days. Lanes (5) and (7) = AjA 1 mg at
14 and 21 days. Lanes (6) and (8) = AjA 5 mg at 14 and 21 days
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CTGF obtained in lungs from animals of all experimen-
tal groups are reported in Fig. 7e and f.
As previously mentioned, PPAR-γ was detectable in
several different types cells in lungs from control mice,
where it appeared to be localized in the cytoplasm. A de-
creased expression of PPAR-γ was seen in lung sections
of mice after BLM challenge (Fig. 8a). Similar to what
observed in the preventive study, the low grade of fibro-
sis detected in AjA-treated groups was accompanied by
enhanced expression of PPAR-γ with an increased
nuclear localization. The values of immunohistochemical
scores for cytoplasmic and nuclear staining of PPAR-γ in
lungs from the various experimental groups are reported
in Fig. 8b.
Representative immunohistochemical reaction for α-
SMA in lung tissue from mice of the various experimen-
tal groups is reported (Figs. 9a). A marked increase of α-
SMA was seen in lung sections of BLM treated mice as
compared with those of control animals at day 21. An
evident reduction of α-SMA positive cells was
Fig. 6 Treatment of AjA in the fibrogenic phase of BLM-lung effectively limits the development of fibrosis as revealed by lung morphology and
morphometry as well as HO-proline content. a Lung slides from mice at day 21 from control mouse, BLM-treated mouse, and mice receiving AjA
at a dose of 1 mg/Kg and 5 mg/Kg at day 8 after BLM delivery. Masson’s trichrome staining, scale bars = 60 μm. b Histologic score in the different
mouse groups. Data are reported as mean ± SD. *p < 0.05 vs control group. † p < 0.05 vs BLM group. c Lung HO-proline expressed as μg/lung in
the various experimental groups. Data are reported as mean ± SD. *p < 0.05 vs control group. † p < 0.05 vs BLM group
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appreciated in AjA treated groups at the different doses
as compared to mice treated with BLM alone. The
values of immunohistochemical score for α-SMA are
shown in Fig. 9b. Similarly, as tested by western blotting
a decreased tissue expression of α-SMA was observed
in AjA treated groups (Fig. 9c, lanes 2 and 3) in re-
spect to mice treated with BLM alone (Fig. 9c, lane
4). In the same figure, α-SMA from control group is
shown in lane 1.
Overall, delayed treatment with AjA effectively limits
the progression of BLM-induced pulmonary fibrosis. It is
noteworthy that the therapeutic AjA treatment seemed to
be equally effective as compared to the “preventive treat-
ment” started at the same day of BLM administration.
Discussion
In this study, we assessed whether AjA, a synthetic
cannabinoid, effective in preventing dermal collagen
Fig. 7 AjA treatment in the fibrogenic phase reduces TGF-β1, pSMAD2/3 and CTGF expression. a Immunohistochemical staining of TGF-β1 at day
14 after BLM delivery in lung sections from control mouse, BLM-treated mouse with consolidated area of fibrosis, and mice receiving at day 8
from BLM delivery AjA at a dose of 1 mg/Kg and 5 mg/Kg. Scale bars = 60 μm. b Imunohistochemical staining of pSMAD2/3 in lung sections from
the different experimental groups at day 14. Scale bars = 60 μm. c Representative immunohistochemical staining of CTGF in lung sections from
the different experimental groups. Scale bars = 60 μm. d ELISA analysis of TGF-β1. BLM increased tissue levels of TGF-β1. e-f immunohistochemical
score for pSMAD2/3 and CTGF in the different experimental groups. * p < 0.05 vs control; † p < 0.05 vs BLM
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accumulation in a model of systemic sclerosis [16, 17] pre-
vents and/or limits lung fibrosis induced by BLM treat-
ment. Specifically, we first show that the preventive use of
AjA (starting the same day of BLM instillation) counter-
acts lung fibrosis by reducing inflammation and thus myo-
fibroblast differentiation and accumulation.
Myofibroblasts are metabolically active in producing
extracellular matrix proteins and in particular interstitial
collagens. It is widely accepted that myofibroblast differ-
entiation, induced by TGF-β1 and characterized by de
novo expression of α-SMA, is a key event in wound heal-
ing and in the pathogenesis of fibrosis.
Our in vivo experiments show that BLM-induced fibro-
sis is attenuated in mice treated with either 1 mg/Kg or
5 mg/Kg of AjA, given 1 h before BLM treatment and
then once a day for the following 8, 14 and 21 days. Gene
Fig. 8 AjA treatment in the fibrogenic phase increases the number PPAR-γ positive cells as well as the nuclear localization of the receptor.
a Representative immunohistochemical staining of PPAR-γ in lung sections from the different experimental groups at 14 day after BLM challenge.
PPAR-γ positive cells were significantly decreased after BLM challenge. Additionally, the nuclear stain for this receptor was very low in lung sections of
control and BLM treated mice. AjA treatments at different doses significantly increase the number of PPAR-γ positive cells and its nuclear stain in lung
slides. Scale bars = 60 μm. b The immunohistochemical score of cytoplasmic and nuclear staining for PPAR-γ in lung tissue from the various
experimental groups is shown
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expression of products implicated in fibrogenesis (TGF-
β1, α-SMA, pSMAD2/3, CTGF and PPAR-γ), as well as
histological and biochemical hallmarks of fibrosis are pro-
foundly modified by the preventive AjA administration.
It is well recognized that therapeutic interventions that
interrupt the inflammatory phase are often protective in
BLM-induced lung fibrosis [25]. Unfortunately, the same
interventions are ineffective in human IPF. Therefore, it
is important to assess the ability of any potential thera-
peutic agent to reduce lung fibrosis when delivered in
the early fibrotic phase (i.e. 7/8 days after BLM delivery)
[25, 26].
On this basis, more clinical relevant is the observation
that AjA still effectively limits pulmonary fibrosis - by
Fig. 9 AjA treatment in the fibrogenic phase significantly decreases the expression of α-SMA in lungs of BLM treated-mice. a Immunohistochemical
staining of α-SMA at day 21 after BLM delivery in lung section from control mouse, BLM-treated mouse with consolidated area of fibrosis, and mice
receiving at day 8 from BLM delivery AjA at different doses. Scale bars = 60 μm. b Immunohistochemical score of α-SMA in the lungs of the different
experimental groups. * p < 0.05 vs control; † p < 0.05 vs BLM. c Representative Western blot analysis of α-SMA from total lung samples of control,
BLM-instilled and AjA-treated mice at 21 days after BLM challenge. Lane (1) = control sample. Lane (2) = BLM + AjA 5 mg. Lanes (3) = BLM+ AjA 1 mg.
Lanes (4) = BLM-instilled sample
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interfering with fibrogenic mechanism (s) and in particu-
lar by reducing myofibroblast accumulation and differ-
entiation—when the treatment started at day 8 after
BLM delivery. The beneficial effects we observed in this
experiment are comparable to those observed in animals
treated in the preventive manner. The reduction of col-
lagen deposition, the morphometric scores of fibrosis
and the changes in the expression of gene products re-
lated to fibrogenesis were similar to those observed in
animals in which AjA treatment started at the same day
of BLM administration.
Although we do not have conclusive explanations for
these findings, it may be assumed that the therapeutic
effects of AjA treatment both in inflammatory or in
early fibrogenic phase are related to the nature (anti-in-
flammatory and anti-fibrotic) of this cannabinoid. For
some time AjA has been mainly considered to exert
anti-inflammatory activities [27]; however, recent data
obtained in a model of systemic sclerosis suggest that
AjA also posses anti-fibrotic properties [16, 17].
It has been recently shown that AjA directly and spe-
cifically binds to PPARγ, a transcription factor belonging
to the nuclear hormone receptor family, that is widely
expressed in immune cells and in many tissues (colon,
spleen, liver, skeletal muscle, lung) [28, 29]. Very import-
ant findings obtained in different vitro studies demon-
strated that AjA increases the transcriptional activity of
PPARγ [30] that in turn prevents the translocation of
NF-κB protein from the cytoplasm to the nucleus
[31, 32], resulting in a reduced production of pro-
inflammatory cytokines, metalloproteases and acute-
phase proteins [30, 33].
Moreover, recent in vivo studies confirm that the
modulation of PPAR-γ activity in the lung can influence
inflammatory and immune response in endotoxemia
[34] and in other pulmonary diseases, such as COPD
and asthma [35].
PPAR-γ activation also plays important role in regulat-
ing processes related to fibrogenesis, including cellular
differentiation and wound healing both in vitro and in
vivo [29, 36]. Moreover, treatment with PPAR-γ ligands
in a variety of mouse models ameliorated lung fibrosis
[37–40].
Even though the molecular basis of the anti-fibrotic
activity of AjA are far from clear, the recently reported
relationship between the endocannabinoid system and
PPAR-γ signalling pathway [41] suggests the possibility
that AjA antifibrotic effects may be directly mediated
through PPAR-γ action.
PPARγ synthetic ligands can interfere with TGF-β1
signaling in a SMAD-dependent way, thus counteracting
the profibrotic effect of TGF-β1 [38, 42]. Consistent with
these findings, we observed that after BLM administra-
tion the increased TGFβ1 expression and the activation
of the TGF-β1 signalling pathway (as revealed by phos-
phorylated SMAD2/3) increased CTGF and α-SMA ex-
pression as well as the expression of collagen genes. The
increased TGFβ1 expression was mirrored by a con-
comitant decrease of PPAR-γ expression.
As observed in the current study, AjA treatment both
in inflammatory or in early fibrogenic phase does reduce
the expression of TGFβ1 stimulating expression of the
endogenous PPAR-γ and more interestingly its nuclear
translocation. This may explain why also in the fibro-
genic phase AjA can counteract the progression of fibro-
sis. Actually, PPAR-γ activators may oppose the
fibrogenic effects of TGFβ1 by inhibiting fibroblast dif-
ferentiation [29] or by modifying myofibroblast pheno-
type [43, 44].
The present study provides the first evidence on the
efficacy of AjA as anti-fibrogenic agent in the lung. AjA
can interfere with TGF-β1 pathway that leads to CTGF,
α-SMA and COL1 and COL2 hyper-expression resulting
in epithelial-mesenchymal transdifferentation and colla-
gen deposition in lungs. The increase in the expression
of PPAR-γ may also influence multiple regulatory path-
ways involved in fibrogenesis [38, 42]. Unfortunately, the
mechanisms by which PPAR ligands alter fibrosis are
not well understood, and additional work is necessary in
this field.
Although BLM model does not completely mimic the
clinical progression of IPF in patients [45, 46] and has
significant limitations regarding the slow and irreversible
progression of fibrosis, the BLM animal model is widely
used for the assessment of potential anti-fibrotic agents.
By using BLM model a large number of compounds
have been shown to prevent fibrosis progression and
have been suggested for clinical testing. However, to date
none of these drugs have shown comparable success in
IPF patients. One major issue is that most agents were
given to the animals in a preventive regimen, prior to or
simultaneous with BLM. In this setting, the drug action
reflected more their anti-inflammatory activity than their
capacity of influencing the subsequent events leading
to fibrosis. When anti-fibrotic ability is considered,
very few compounds resulted “true” anti-fibrotic
agents if administered during the “fibrotic” phase of
the BLM model.
Conclusions
In conclusion, like very few other compounds AjA
exerts potent anti-fibrotic effect when given during
the fibrogenic phase of BLM lung. Further clinical
studies are necessary to establish whether AjA may
represent a new therapeutic option for treating hu-
man IPF, or other fibrotic lung diseases refractory to
corticosteroids.
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